Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?
Open Access
- 2 March 2004
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 90 (7), 1349-1360
- https://doi.org/10.1038/sj.bjc.6601710
Abstract
Contrast-enhanced (CE) MRI was used to monitor breast cancer response to neoadjuvant chemotherapy. Patients underwent CE MRI before and after therapy, together with conventional assessment methods (CAM). CE MRI was carried out at 1.5 T in the coronal plain with 3D sequences before and after bolus injection. An expert panel determined chemotherapy response using both CE MRI and CAM. Histopathological response in the surgical specimen was then used to determine the sensitivity and specificity of CE MRI and CAM. In total, 67 patients with 69 breast cancers were studied (mean age of 46 years). Tumour characteristics showed a high-risk tumour population: median size 49 mm: histopathological grade 3 (55%): oestrogen receptor (ER) negative (48%). Histopathological response was as follows: - complete pathological response (pCR) 17%; partial response (pPR) 68%; no response (NR) 15%. Sensitivity of CAM for pCR or pPR was 98% (CI 91-100%) and specificity was 50% (CI 19-81%). CE MRI sensitivity was 100% (CI 94-100%), and specificity was 80% (CI 44-97%). The absolute agreement between assessment methods and histopathology was marginally higher for CE MRI than CAM (81 vs 68%; P=0.09). In 71%, CE MRI increased diagnostic knowledge, although in 20% it was judged confusing or incorrect. The 2nd MRI study significantly increased diagnostic confidence, and in 19% could have changed the treatment plan. CE MRI persistently underestimated minimal residual disease. In conclusion, CE MRI of breast cancer proved more reliable for predicting histopathological response to neoadjuvant chemotherapy than conventional assessment methods.Keywords
This publication has 45 references indexed in Scilit:
- Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancerBritish Journal of Cancer, 2002
- Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breastEuropean Journal of Surgical Oncology, 2001
- MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast CancerAnnals of Surgical Oncology, 2001
- The Diagnostic and Therapeutic Impact of MRI: an Observational Multi-centre StudyClinical Radiology, 2000
- Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre studyMagnetic Resonance Imaging, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Observer variability in the interpretation of contrast enhanced MRI of the breastThe British Journal of Radiology, 1996
- Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imagingCancer, 1996
- Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammographyBreast Cancer Research and Treatment, 1996
- pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upHistopathology, 1991